Abstracts tagged "Administrative Data"

Abstract Number: 1315 • ACR Convergence 2024
From Presentation to Publication: Tracking the Publication Rate of Abstracts Presented at American College of Rheumatology Convergence Conference in the Years 2015 and 2018
Shreena Kamlesh Gandhi¹, Shivani Patel², Saransh Narang³, Aayushi Rajani³ and Kaleb Michaud⁴, ¹KU School of Medicine, Wichita, Wichita, KS, ²Washington University in St. Louis, St. Louis, MO, ³Medical College, Baroda, Baroda, India, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR Convergence meeting attracts rheumatology researchers worldwide to present their peer- reviewed abstracts for a global audience either as a poster or oral…
Abstract Number: 2491 • ACR Convergence 2024
Treatment Outcomes of Eosinophilic Granulomatosis with Polyangiitis (EGPA):A Retrospective Analysis of US Health Insurance Claims Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, Danuta Kielar⁵, Juliana Meyers⁶, Elizabeth Esterberg⁶, Tram Nham⁶ and Stephanie Y. Chen⁷, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom, ⁶RTI Health Solutions, Research Triangle Park, NC, ⁷BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis disorder characterized by asthma, eosinophilia and the presence of eosinophilic inflammation. Patients with EGPA are…
Abstract Number: 0199 • ACR Convergence 2024
Delivery of Guideline Concordant Care in Childhood-Onset Lupus Nephritis
Alisha Akinsete¹, Mangala Rajan², Orysya Soroka², Karen Onel³, Monika Safford² and Iris Navarro Millan⁴, ¹Weill Cornell Medicine/ Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY, ³HSS, New York, NY, ⁴Weill Cornell Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: 50-80% of children with childhood-onset systemic lupus erythematosus (cSLE) develop lupus nephritis (LN). Children from historically marginalized communities are disproportionately affected by cSLE and…
Abstract Number: 1606 • ACR Convergence 2024
Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data
Paul Dolin¹, Anat Shavit¹, Karina A. Keogh², Jennifer Rowell³, Chris Edmonds⁴, James M. Eudicone⁵, Amanda M. Moore⁶, Melissa Wilson⁷, Kinwei A. Chan⁶, Thomas Peer⁸ and Stephanie Y. Chen⁹, ¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ²Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic,, Rochester, MN, ³Market Access and Pricing, AstraZeneca, Cambridge, England, United Kingdom, ⁴Market Access and Pricing, AstraZeneca, Gaithersburg, MD, ⁵Real World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ⁶TriNetX, Cambridge, MA, ⁷TriNetX, Durham, NC, ⁸TriNetX, Farmington, NY, ⁹BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disorder characterized by chronic necrotizing vasculitis. Conventional therapy (oral glucocorticoids [OGC] ± immunosuppressants), mepolizumab, and…
Abstract Number: 2587 • ACR Convergence 2024
A Proprietary AI Rule Engine Assisted by an OpenAI-based ML Model Can Speed up and Better Inform the Prior Authorization Process for Rheumatology Investigations and Medications
Tanishka Agrawal¹, Sumanth Raman², J. Arun³ and HUMEIRA BADSHA⁴, ¹Dubai International Academy, Dubai, Dubai, United Arab Emirates, ²Algorithm Health, Dubai, Dubai, United Arab Emirates, ³Algorithm Health, Dubai, United Arab Emirates, ⁴HBMC, Dubai, United Arab Emirates
Background/Purpose: Patients with chronic autoimmune conditions often need expensive treatments which require prior authorizations by insurance companies. However, significant delays in these processes leave patients…
Abstract Number: 0202 • ACR Convergence 2024
Survival in Patients with Rheumatoid Arthritis and Early-Stage Colorectal, Lung, or Prostate Cancer Receiving Tumor Necrosis Factor Alpha Inhibitors
Maria Suarez-Almazor¹, Juan Ruiz², Xiudong Lei¹, Hui Zhao¹, Suja Rajan³, Heather Lin¹ and Sharon Giordano¹, ¹MD Anderson Cancer Center, Houston, TX, ²MD Anderson, Houston, TX, ³The University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: There is concern about the use of tumor necrosis factor inhibitors (TNFi) in patients with early cancer given their immunosuppressant effects. Few studies have…
Abstract Number: 1716 • ACR Convergence 2024
Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Kasra Moolooghy¹, Hui Xie², Yufei Zheng³, J. Antonio Avina-Zubieta¹ and Diane Lacaille¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Various classes of biologic and targeted synthetic DMARDs (b/tsDMARDs) are now available for treatment of inflammatory arthritis (IA), but little information on their relative…
Abstract Number: 2621 • ACR Convergence 2024
Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records
David Cheng¹, Vidul Panickan², Andrew Cagan³, Gregory McDermott⁴, Mary Jeffway³, Ying Qi⁵, Feng Liu³, Michael Weinblatt⁶, Nancy Shadick⁵, Tianxi Cai⁷ and Katherine Liao³, ¹Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Brookline, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Systematic measurement and documentation of disease activity in RA patients is key for monitoring quality of care and is an important outcome and predictor…
Abstract Number: 0183 • ACR Convergence 2023
Barriers and Facilitators to Recruiting Underrepresented Participants for Clinical Trials: Insights from the Lupus Clinical Investigators Network (LuCIN)
Tessa Englund¹, Christine Lee², Julie Hsieh², Richardae Araojo², Julia Mariano¹, Emily McCormick³, Stacie Bell⁴, Albert Roy⁵ and Saira Sheikh¹, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²U.S. Food and Drug Administration, Silver Spring, MD, ³Thurston Arthritis Research Center, Chapel Hill, NC, ⁴Lupus Therapeutics, Lakewood, CO, ⁵Lupus Research Alliance, New York, NY
Background/Purpose: Despite greater prevalence of lupus among diverse, racial and ethnic minority populations, marked gaps exist between populations affected by lupus and those enrolled in…
Abstract Number: 1027 • ACR Convergence 2023
Single-Payer Health Insurance May Not Mitigate Income-Based Differences in Total Hip Arthroplasty Utilization: A Transnational Analysis
Bella Mehta¹, Kaylee Ho², J. Alex Gibbons³, Vicki Ling⁴, Susan Goodman⁵, Michael Parks⁵, Bheeshma Ravi⁶, Fei Wang², Said Ibrahim⁷ and Peter cram⁸, ¹Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Columbia University Vagelos College of Physicians & Surgeons, New York, NY, ⁴Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶Sunnybrook Health Sciences Centre, Toronto, ON, Canada, ⁷Northwell Health, New York, NY, ⁸The University of Texas Medical Branch, Galveston, TX
Background/Purpose: Access to care varies across health systems. Countries with universal health insurance are thought to have less wealth-based health disparities, but it is unclear…
Abstract Number: 1818 • ACR Convergence 2023
Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Ye Liu¹, Tarun Arora², Jeffrey Curtis¹ and Jingyi Zhang¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL
Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…
Abstract Number: 0353 • ACR Convergence 2023
Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods
Patricia Hoffman¹, Lauren Parlett², Daniel Beachler², Daniel Reiff³, Sarah McGuire¹, Sonia Pothraj¹, Lakshmi Moorthy¹, Cynthia Salvant⁴, Dawn Koffman⁵, Sanika Rege⁵, Cecilia Huang⁵, Matthew Iozzio⁵, Kevin Schott², Kevin Haynes⁶, Amy Davidow⁷, Stephen Crystal⁸, Tobias Gerhard⁵, Brian Strom⁹, Carlos Rose¹⁰ and Daniel Horton⁴, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Carelon, Wilmington, DE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁵Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, ⁶Janssen Pharmaceuticals, Raritan, NJ, ⁷New York University, New York, NY, ⁸Rutgers University, New Brunswick, NJ, ⁹Rutgers, State University of New Jersey, New Brunswick, NJ, ¹⁰Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Administrative claims databases represent important settings for studying large populations with juvenile idiopathic arthritis (JIA), but prior efforts to validate diagnostic algorithms for JIA…
Abstract Number: 1030 • ACR Convergence 2023
Patterns in the Prescription, the Denials of Coverage, and the Delays in Dispensation of Janus Kinase Inhibitors
Thomas Riley¹, Igor Dombrovsky², Michael George³ and Joshua Baker³, ¹Hopsital of the University of Pennsylvania, Springfield, PA, ²Pennsylvania Hospital, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Janus kinase inhibitors (JAKi) have therapeutic benefits in autoimmune conditions. Access to these medications is controlled by insurance carriers through requirements for prior authorizations…
Abstract Number: 1856 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project
Kathlyn Camargo Macias¹, Ravi Shahu Khal¹, Ariail Schmitz², Kathleen McCabe¹, Taylor Kann¹, Marilyn Mosquera³ and Ashwini Komarla⁴, ¹University of Central Florida, Orlando, FL, ²University of Central Florida, St. Cloud, FL, ³University of Central Florida, Casselberry, FL, ⁴ORLANDO VAMC, Orlando, FL
Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…
Abstract Number: 0433 • ACR Convergence 2023
DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Una Makris², Namrata Singh³, Raymond Yung⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX, ³University of Washington, Bellevue, WA, ⁴Michigan Medicine, Ann Arbor, MI
Background/Purpose: The number of older adults living with rheumatoid arthritis (RA) is growing as the world population is aging. Up to one-third of the older…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].